Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 5/20 | 0.30 |
| ▸ | CNR2 | P34972 | 4/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | ATF4 | P18848 | 1/20 | 0.30 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268838 | 0.95 | PIK3CD (0.33) | PIK3CDCNR1CNR2HPGDATF4 | |
| SCHEMBL31268804 | 0.94 | PIK3CD (0.37) | PIK3CDHTTCNR1CNR2HPGD | |
| SCHEMBL31269024 | 0.92 | PIK3CD (0.33) | PIK3CDHTTCNR1CNR2HPGD | |
| SCHEMBL31269416 | 0.91 | PIK3CD (0.33) | PIK3CDHTTHPGDATF4 | |
| SCHEMBL31268824 | 0.90 | PIK3CD (0.34) | PIK3CDCETPLMNA | |
| SCHEMBL31268898 | 0.89 | PIK3CD (0.33) | PIK3CDCETPLMNA | |
| SCHEMBL31269264 | 0.89 | ABL1 (0.35) | PIK3CDGPR119CNR1CNR2MEN1 | |
| SCHEMBL31268974 | 0.88 | ALDH1A1 (0.35) | PIK3CDHTTCNR1CNR2CETP | |
| SCHEMBL31269086 | 0.88 | PDE2A (0.33) | PIK3CDGPR119 | |
| SCHEMBL31268819 | 0.87 | PIK3CD (0.36) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |